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Abstract: Personalised and model-based clinical care is on the rise and offers significant opportunity to 
improve care and productivity in response to rising demographic demands and rising costs. Compliance 
in critical care is important for any protocolised clinical care. However, it is often overlooked and very 
infrequently studied. Critically ill patients often experience stress-induced hyperglycemia, which has 
been shown to result in increased morbidity and mortality. Safe, effective glycemic control (GC) can 
reduce mortality and improve outcomes, but is only effective if strong compliance is observed within the 
clinical practice. This study examines insulin-nutrition dosing compliance for STAR, a tablet-based 
protocol designed to easily adapt to variable clinical practice, its neonatal intensive care unit version 
GRYPHON, and a standard paper based clinical protocol (CHU). All interventions and changes were 
recorded for all three cohorts, and a sub-cohort was used to examine the validity of the data used. 
Compliance was over 99% for STAR, over 98% for GRYPHON and 80% for CHU. The differences is 
attributed primarily to interface design and its focus on ease of use and natural use for clinical staff. 
However, while compliance is higher, the reasons for good compliance in any such system remains to be 
more precisely specified with appropriate research tests.  
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Hypoglycaemia, hyperglycaemia, and blood glucose (BG) 
variability are associated with higher mortality and worsened 
outcomes in critical care units (ICU), including severe 
infection, sepsis and septic shock, myocardial infarction, and 
multiple organ failure (McCowen et al., 2001, Capes et al., 
2000, Krinsley, 2003, Krinsley, 2009, Bagshaw et al., 2009, 
Van den Berghe et al., 2006a). Early studies showed benefits 
from intensive insulin therapy in the ICU (Van den Berghe et 
al., 2001a, Van den Berghe et al., 2003, Krinsley, 2004, 
Chase et al., 2008b), with improved outcomes (Chase et al., 
2010, Van den Berghe et al., 2003), reduced mortality, and 
reduction of patient length of stay and nurse workload 
(Krinsley, 2005, Van den Berghe et al., 2006b). However, 
more recent trials have failed to reproduce these results, and 
have shown higher risks of hypoglycaemia (Griesdale et al., 
2009, Wiener et al., 2008, Preiser et al., 2009, Finfer et al., 
2009). 
 
One explanation for these conflicting results is the role of 
increased hypoglycaemia and BG variability in confounding 
results (Bagshaw et al., 2009, Egi et al., 2010, Penning et al., 
2014a, Krinsley et al., 2015). To adequately test the improved 
outcome hypothesis, insulin therapy must be carried out in a 
safe and effective manner, and be consistently achieved for 
all or nearly all patients (Chase et al., 2010). In addition, 
glycaemic control protocols must effectively manage 
metabolic variability, which drives glycaemic outcome 
(Chase et al., 2011c). Thus, fixed table-based or ad hoc 
protocols, often used in hospital ICUs, lack patient specificity 
and rely on clinical judgement, often failing to account for 
such variability. 
 
STAR (Stochastic TARgeted) is a clinically validated model-
based glycaemic control framework (Evans et al., 2012, Fisk 
et al., 2012, Stewart et al., 2016). It uses model-based insulin 
sensitivity to characterise and forward predict changes in 
metabolic state. Insulin and nutrition treatments are selected 
such that forward predictions of likely BG outcomes are 
within the target range, and the treatment does not exceed a 
5% likelihood of BG ≤ 4.0 mmol/L. STAR has delivered 
virtually identical glycemic control in very different ICUs in 
ICUs in the Christchurch, New Zealand, and Gyula, Hungary, 
demonstrating its strong ability to generalise across patients 
and units, which no other clinical protocol has been able to 
do to date (Stewart et al., 2016). 
 
Thus, one major lesson to date is model-based, personalised 
glycemic control has proven much more capable than 
clinical, ad-hoc methods in providing quality control. This 
outcome has been shown with STAR and a few other 
protocols (Stewart et al., 2016, Blaha et al., 2016). However, 
the original, very successful Leuven protocol from the 
original study by van den Berghe et al was not only very 
successful (Van den Berghe et al., 2001b), but outperformed 
a very good model-based system (Dubois et al., 2017). 
 
The main question is thus what limited the clinical 
protocols from achieving these outcomes? 
 
 
     
 
 
Workload is one factor (Mackenzie et al., 2005, Aragon, 
2006). The inability to personalise care and create “one 
method fits all” approaches instead of “one size fits all” plays 
a major role (Chase et al., 2011a, Chase et al., 2011b), as 
many clinical protocols are not able to provide good control, 
unlike the Leuven protocol. 
 
This analysis leaves protocol compliance as a potential major, 
often overlooked source of variability. The NICE-SUGAR 
trial showed negative results, but had non-compliance rates 
up to 50% or more in an independent analysis (Uyttendaele et 
al., 2017b), as they did not monitor compliance (Finfer et al., 
2009). Hence, non-compliance impacts performance, safety 
and thus outcomes (Uyttendaele et al., 2017a). 
 
This study analyses compliance for a computerised model-
based protocol, STAR (Stewart et al., 2016), a widely used 
neonatal ICU (NICU) version (GRYPHON) (Alsweiler et al., 
2017, Dickson et al., 2018), and a clinical protocol from a 
third ICU. It thus assesses the impact of computer interfaces 




Three protocols are examined: 
 
1. STAR (Stewart et al., 2016): as used in the adult ICU in 
Christchurch, New Zealand as a standard of care since 2011. 
2. GRYPHON (Dickson et al., 2018): as used in the 
Christchurch Women’s Hospital, Christchurch, New Zealand 
as a standard of care since 2010 
3. CHU (Dickson et al., 2017): a clinical protocol used in 
CHU de Liege, Belgium since 2013 
 
STAR and GRYPHON are model-based and personalised 
and model predictive. They represent the emerging mix of 
computation and health care. Both provide performance well 
above reported clinical studies. CHU provides relatively good 
control and a computer-free clinical protocol comparator. 
 
STAR and GRYPHON directly save all clinical and 
intervention dose data on tablets. CHU data was recorded 
directly from patient data sheets. All data and anonymised 
use was approved by the NZ National Ethics Committee 
(STAR and GRYPHON) and the Ethics Committee of the 
Medical Faculty of the University of Liege, Belgium (CHU). 
2.2 Compliance and Analyses: 
Compliance is defined as not changing the recommended 
dose. Every BG measure, as specified by a protocol leads to 
another intervention. Where a recommendation is changed, it 
is counted as non-compliance. It is recorded per-patient. Each 
patient has a compliance value for each type of intervention 
(insulin, nutrition). Results are reported as mean compliance 
across the entire cohort for each protocol and intervention. 
 
STAR modulates both insulin and nutrition. It gives insulin in 
either bolus or infusion, yielding three values. GRYPHON 
modulates only insulin, leaving nutrition to clinical standards, 
so there is only one compliance value. CHU controls insulin 
only and leaves nutrition to local guidelines. Performance has 
been reported elsewhere for all 3 cases (Dickson et al., 2018, 
Dickson et al., 2017, Stewart et al., 2016). 
 
A sub-analysis is run for STAR, which has the most clinical 
data and patients. It examines 23 patients (~10% of patients 
and hours). It compares compliance on the tablet to data on 
bedside charts. Note the STAR sub-cohort was statistically 
similar to the STAR cohort in Age, Sex, and length of stay, 
% surgical, APACHE II score, and glycemic control. This 
analysis assesses if nurses were “honest” with the STAR 
tablet system and if compliance varies in an unknown way. 
 
Glycemic control performance for each protocol was similar 
to all reports referenced. It is not reported as each targets 
different bands and has different approaches. Hence, the 
study considers only compliance to protocol recommendation 
in this analysis. Results are reported as median [IQR =inter-
quartile range] across the cohort and compared using Mann-
Whitney tests and p < 0.05 is considered significant. 
 
Overall, this study assesses compliance for two model-based 
and one clinical protocol. It validates the model-based cases 
based on a test comparison to a sub-cohort of patients to 
ensure compliance reported by tablet software is as reported 
on the official bedside medical charts. The goal is to assess 




Table 1 reports mean compliance for all protocols. STAR and 
GRYPHON have very high compliance over 95%. CHU has 
relatively high compliance of 80%, but this value is still 
much lower than the model-based systems with personalised, 
model-based control even though it is higher than some 
clinical reports and analyses with ~50% compliance. Table 2 
compares STAR and the STAR sub-cohort. The results show 
there is no clinically or statistically significant differences in 
results between using the tablet reported data and direct 
examination of the bedside charts, despite searching for likely 
cases. It is thus a worst case analysis.  
 
Table 1:  Mean recommendation compliance in percent  
 STAR GRYPHON CHU 
#Patients 258 35 20 
#Hours 20692 3180 5006 
# BG 11180 886 1391 
    
Insulin 
Bolus 
99.6% NA NA 
Insulin 
Infusion 
99.5% 95.6% 80.8% 
Nutrition 
Rate 
96.8% NA NA 
 
Overall, the results in Table 2 validate the overall analysis 
from the tablet computer data. It is worth noting again that 
 
 
     
 
the cohorts were also statistically similar. In addition, 
GRYPHON is a similar system and approach to STAR, and 
is used in the same two hospital setting in Christchurch, so 
the results are assumed to hold for this case, as well.  
 
Table 2:  STAR vs STAR Sub-Cohort compliance analysis  
 STAR STAR Sub-
Cohort 
P-value 
#Patients 258 23  
#Hours 20692 1704  
# BG 11180 921  















EN Rate 96.6 
[90.9: 100.0] 
98.2  
[93.6 : 100.0 
0.44 
PN Rate  98.2 
[92.4: 100.0] 
100.0  





Table 1 shows while CHU had good compliance compared to 
many protocols at 80% (Uyttendaele et al., 2017b, Mackenzie 
et al., 2005, Anger et al., 2006, Rood et al., 2005), it is well 
below the 96.8-99.6% for STAR and GRYHON. These 
outcomes match other studies showing improved compliance 
with computerised protocols, model-based or otherwise 
(Anger et al., 2006, Mann et al., 2011, Morris et al., 2008, 
Rood et al., 2005). The results show the impact of human 
factors, where paper-based clinical protocols are potentially 
harder to use (Carayon et al., 2014, Chase et al., 2008a).  
 
Equally, a computer interface, regardless of algorithm 
efficacy, can deliberately offer better design for use. This 
design for human factors was deliberte for STAR (Ward et 
al., 2012) and GRYPHON. In addition, it can be used to 
reduce errors in numerical calculation or recording (Ward et 
al., 2012), which have up to 10% of incidence (Campion et 
al., 2010). Thus, well-designed computer interfaces offer 
potentially improved compliance and error reduction. 
 
Table 2 sub-cohort analysis shows Christchurch staff were 
highly compliant and validates the tablet data was accurate to 
the true record on bedside charts. This validation comparison 
is a worst case analysis because the sub-cohort cases were 
selected for “suspicious behaviour” deviating from typical 
profiles of therapeutic dosing.  
 
GRYPHON is assumed to have similar compliance as STAR 
based on 2 main points. First, Christchurch Women’s 
Hospital is next to Christchurch Hospital and shares overall 
clinical and hospital culture. Second, the GRYPHON and 
STAR interface designs are very similar, sharing all major 
details, with only minor differences due to cohort. However, 
it remains to be verified. CHU data was recorded from the 
bedside chart data and is thus the “truest” data available.  
 
Finally, while clinical staff could be untruthful about what 
they record on the patient bedsheet, it is a major offence and 
very unlikely. Thus, the comparison to bedside chart data is 
as close to a gold standard truth as possible. In future, as 
devices become more integrated via the internet of things 
(IoT) (Whitmore et al., 2015) these data will be able to be 
cross checked. This future is increasingly likely as seen in the 
growth of cloud and web-based data services in medicine. 
 
There are limitations to this study. First, there is only a single 
clinical protocol (CHU). Clinical protocols and their ease of 
use, and thus compliance can vary significantly (Chase et al., 
2008a). The factors that lead to non-compliance are thus very 
varied and not always easily explained. 
 
For example, a main area of compliance comes from trust in 
the protocol (Chase et al., 2008a). Trust in a clinical setting 
arises typically from safety and performance, particularly in 
glycemic control where poor control has negative outcomes 
(Finfer et al., 2012, Krinsley, 2008, Krinsley et al., 2011, 
Krinsley, 2003) and good control has positive impact 
(Krinsley et al., 2015, Signal et al., 2012). Thus, it may not 
be possible to separate the quality of the protocol and its 
glycemic control, and the compliance seen. There is not yet a 
study comparing compliance in two protocols using the same 
interface, though one is ongoing (Alsweiler et al., 2017). 
 
Trust is also a factor that is gained with increasing confidence 
in a system due to observed positive results and repeated use 
and support. Thus pilot trials are essential to the 
implementation of a new “smart” or computer-based 
protocol, where clinical staff have the opportunity to closely 
observe outcomes. However, it is worth noting that for these 
pilot trials, compliance must be insisted upon and enforced 
where clinically reasonable, otherwise new applications are 
undermined before they are even able to prove themselves. 
 
Finally, it has been observed that non-compliance in the 
protocols shown here are due in part to caution (Penning et 
al., 2012, Penning et al., 2014b). This outcome supports the 
prior discussion, where in this case nursing staff reduce 
insulin dosing for fear of hypoglycemia and its negative 
impact on outcome.  It thus suggests that compliance will 
vary with trust, exposure and training/experience, which 
remains to be verified in an appropriate test or trial. 
 
However, it was also noted nursing staff used to clinical 
protocols often consider varying the dose. In particular, 
nurses reported they varied doses to manage patient 
variability, which defines glycemic control and its difficulty 
in these cohorts (Chase et al., 2011b, Pretty et al., 2012). 
More specifically, they manage patient variability by 
deliberately varying from the overall clinical protocol.  
 
In contrast, personalised model-based methods, such as 
STAR and GRYPHON, manage variability directly. Where 
STAR and GRYPHON are successful in building trust 
around clinical compliance is they seek to communicate how 
variability is managed and accounted for. Figure 1 shows an 
interface screenshot, where clinical staff are offered several 
options for treatments, which they are free to select based on 
 
 
     
 
their own clinical equipoise. Their decision making process is 
assisted by the graph, which shows the 90% likelihood range 
of possible glycaemic outcomes for each treatment. Thus, 
STAR and GRYPHON show the reasoning for the treatments 
offered, even as each treatment arises from complex 
simulation. Clinical feedback indicate such graphs supporting 
treatment options aid clinical staff in their decision making 
process, by increasing understanding of treatment choices. 
 
Thus, any transition into cyber-physical systems mixing 
clinical care with significant computation must directly 
consider clinical equipoise and the communication of how 
direct management of variability is achieve in the training 
delivered. This will likely also involve end-used consultation 
with interface design to ensure the most natural transition and 
thus, potentially, the best compliance. Again, these 
conclusions remain to be tested directly. 
 
 
Figure 1: Example of STAR and GRYPHON interface 




Personalised and model-based clinical care is on the rise and 
offers significant opportunity to improve care and 
productivity in response to rising demographic demands and 
rising costs. Compliance in critical care is important for any 
protocolised clinical care. However, it is often overlooked 
and very infrequently studied.  
 
This study compared compliance of two personalised and 
model-based decision support systems for glycemic control 
in critical care with a typical sliding scale styled paper 
protocol. Compliance was 25% higher (relatively, 18-19% 
absolute) for the model-based decision support systems, even 
though the clinical protocol had compliance far higher than 
seen in some other studies with similar protocols. The 
differences is attributed primarily to interface design and its 
focus on ease of use and natural use for clinical staff. 
However, while compliance is higher, the reasons for good 
compliance in any such system remains to be more precisely 
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